domingo, 12 de diciembre de 2010

Tratamiento de la fibromialgia

 

----- Mensaje reenviado ----
De: Victor Whizar-Lugo <vwhizar@anestesia-dolor.org>
Para: maximocuadros@yahoo.es
Enviado: dom,12 diciembre, 2010 08:07
Asunto: Tratamiento de la fibromialgia

 Anunciate con Anestesia-Dolor

Anestesia y Medicina del Dolor
Siguenos en:
Find us on Facebook Follow us on Twitter
Próximos Eventos
  
siguenos en facebook
Registrate con nosotros
Registrate a nuestra lista 
Conoce México
Ligas
 

No:343     

Diciembre 12, 2010
 Colores de Mexico

Estimad@ Maximo Jesus Cuadros Chavez:

Farmacoterapia de la fibromialgia: enfoque sobre duloxetina

Pharmacotherapy of  Fibromyalgia: Focus on Duloxetine
Eric Serra and Michel Andrejak
Amiens, France. Email: serra.eric@chu-amiens.fr
Clinical Medicine: Therapeutics 2009:1 1617-1627

 

Abstract
Context: Fibromyalgia syndrome (FMS) is a frequent medical condition characterized by chronic widespread pain and reduced pain threshold. Associated symptoms include fatigue, non restorative sleep, and psychological distress. As usual in medicine, even if the pathogenesis is unclear, some treatments are useful to help patients. Objectives: Tricyclic antidepressants were the first drugs used to treat FMS. More recently, among serotonin-norepinephrine reuptake inhibitors, duloxetine was approved by US Food and Drug Administration to treat FMS. Duloxetine is used for the management of major depressive disorder, neuropathic pain, generalized anxiety disorder, and stress incontinence. In the pharmacotherapy of  fibromyalgia, a focus is presented on the drug duloxetine. Results: Mechanism of action, metabolism and pharmacokinetic profile are presented. Clinical studies of Duloxetine showed an acceptable efficacy for this chronic condition: Number Need to Treat (NTT) of 4.7 to 9.9, through two 3-month placebo-controlled trials and two 6-month trials. Evaluation criteria are discussed. Safety of this medication has been found to be satisfactory, with nausea as the most common adverse event, in almost 20% of cases. Conclusion: Treatment algorithm for duloxetine is presented inside FMS treatment strategy. With duloxetine, it is important to start low and increase slowly to prevent or minimize adverse events: 30 mg/day up to 60 mg/day in the second week and if necessary up to 90-120 mg/day. It is possible to treat for 3 to 6 months, possibly up to 12 months. The drug could be decreased 2 to 4 weeks before stopping, with regular assessments during this time. International recommendations insist on multimodal treatments: drug and non drug. Also effective for anxiety and depression, duloxetine ranks among the first place drugs for FMS.
Keywords: duloxetine, fibromyalgia, pharmacotherapy.

 

Artí­culo en PDF 

 

Pregabalina y síndrome de fibromialgia: una opción terapéutica.

Pregabalin and Fibromyalgia Syndrome: A Treatment Option
Kim Lawson
Biomedical Research Centre, Sheffield Hallam University, City Campus, Sheffield, S1 1WB, UK. Email: k.lawson@shu.ac.uk
Clinical Medicine: Therapeutics 2009:1 809-824


Abstract: Fibromyalgia (FM) is a chronic complex pain disorder that is multidimensional and exhibits heterogeneity requiring a long-term multidisciplinary approach to management. Many of the drugs used in the treatment of FM have been focused to the management of single symptoms; often such drugs fail to demonstrate acceptable efficacy in the majority of the patient population. Pregabalin is an α2-δ ligand that regulates the release and postsynaptic actions of  neurotransmitters related to analgesic, anticonvulsant and anxiolytic properties. In randomized, double-blind, placebo-controlled studies, pregabalin has demonstrated an improvement in
pain, sleep and fatigue symptoms associated with FM, as well as offering an improvement in parameters related to quality of life. Although the positive outcomes obtained with pregabalin support its use as an option for the management of FM, the efficacy was restricted to a selected patient population outside of the usual care setting. Current data do not allow an explanation where there are any limitations of pregabalin as a treatment of patients with FM, as to whether this is a deficiency of the drug or the process of assessment (e.g. assessment tools of FM, clinical trial design).
Keywords: fibromyalgia, pregabalin, treatment, pain, fatigue, sleep

 

Artí­culo en PDF 

Atentamente
Anestesiología y Medicina del Dolor

No hay comentarios:

Publicar un comentario en la entrada